Recent Breakthroughs in the Application of Advanced Therapy Medicinal Products Based on Mesenchymal Stromal Cells

Dear Colleagues,

The clinical application of stem cells continues to fascinate the scientific and clinical communities. Despite the controversies surrounding this field, it is clear that stem cells have revolutionized regenerative medicine. Cell therapy is a progressively growing field that is moving fast from preclinical model development to clinical application. In this regard, outcomes obtained from clinical trials reveal the therapeutic potential of stem cell-based therapy, which deals with unmet medical needs for several disorders with no therapeutic alternatives. The application of stem cells in regenerative medicine addresses a wide range of clinical conditions using various types of stem cells. Mesenchymal stromal cells (MSCs) have been established as promising candidate sources of universal donor cells for cell therapy due to their contributions to tissue and organ homeostasis, repair, and support by self-renewal and multi-differentiation, as well as their anti-inflammatory, anti-proliferative, immunomodulatory, trophic, and pro-angiogenic properties. Various diseases have been successfully treated with MSCs in animal models. Additionally, hundreds of clinical trials related to the potential benefits of MSCs are in progress or have concluded satisfactorily. However, although all MSCs are considered suitable to exert these functions, dissimilarities have been found among MSCs derived from different tissues. The same levels of efficacy and desired outcomes have not always been achieved in the diverse studies that have been performed thus far. Therefore, collecting information regarding the characteristics and molecular pathology of MSCs obtained from different sources and the influence of other medical and physiological conditions on MSCs is important for understanding the physiopathology of different diseases and ensuring the feasibility, safety, and efficacy of cell-based therapies.

This Special Issue aims to provide a platform for molecular mechanistic research on mesenchymal stem cells and their derivatives, with a particular emphasis on their molecular pathology and diagnostic and therapeutic potentials, in order to update and discuss the state of the art in MSC cell-based therapies and to recapitulate relevant information regarding factors to consider for the clinical application of MSCs. We invite original research and reviews based on molecular and cellular discoveries.

Dr. Abdelkrim Hmadcha
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• advanced therapy
• cell therapy
• clinical trial
• exosomes
• good manufacturing practice
• immunomodulation
• inflammation
• medicinal products
• mesenchymal stromal cells
• molecular pathology
• trophic factors